ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO011

Antiviral Effects of Voclosporin on SARS-CoV-2 in Immunocompromised Kidney Patients

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Arends, Eline Jana, Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
  • Meziyerh, Soufian, Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
  • Moes, Dirk jan, Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
  • Kamerling, Sylvia, Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
  • Van der kooij, Sandra W., Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
  • Ogando, Natacha S., Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
  • Snijder, Eric J., Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
  • Van Hemert, Martijn J., Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
  • Visser, Leo G., Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
  • Feltkamp, Mariet, Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
  • Rabelink, Ton J., Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
  • van Kooten, Cees, Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
  • De Vries, Aiko P.J., Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
  • Teng, Yoe Kie Onno, Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands

Group or Team Name

  • on behalf of all the VOCOVID investigators
Background

Immunocompromised patients, including Kidney Transplant Recipients (KTRs) and lupus nephritis (LN) patients, are at increased risk for prolonged SARS-CoV-2 infection and developing COVID-19-related complications. Recently, we reported that voclosporin, a novel calcineurin inhibitor (CNI), demonstrated in vitro a more potent inhibitory effect on SARS-CoV-2 replication than other CNIs (tacrolimus and ciclosporin). Additionally the AURORA-2 study, where 216 LN patients were treated with voclosporin or placebo on top of standard of care, SARS-CoV-2 infection was detected in 12/100 placebo-treated patients (12%) compared to 7/116 voclosporin treated patients (6%) and more patients died due to COVID-19 in the placebo arm versus voclosporin arm (3% vs 0%). In this proof-of-concept study we assessed whether voclosporin demonstrated an added antiviral benefit in SARS-CoV-2 positive immunocompromised patients.

Methods

We performed a prospective, randomised, open-label, single-center, exploratory, proof of concept study in 20 KTRs with mild to moderate symptoms from a COVID-19 infection comparing time to viral clearance of SARS-CoV-2 between patients on standard immunosuppressive therapy with tacrolimus versus voclosporin (the VOCOVID study).

Results

In the VOCOVID study no difference in time to viral clearance or time to clinical recovery was found between both treatment arms. Pharmacokinetic analysis demonstrated that adequate trough levels of voclosporin were reached from day 4-8 after randomization. Looking at specific timepoint in a post-hoc analysis, indeed a significantly better viral clearance of SARS-CoV-2 was observed in voclosporin treated patients at day 4-8. No safety concerns were raised.

Conclusion

The present study provides evidence that voclosporin has a favorable benefit-risk profile for immunocompromised kidney disease patients who contract a SARS-CoV-2 infection while requiring the continuation of their immunosuppressants.

Funding

  • Commercial Support